Pipeline
In This Section
Our Branded Development Pipeline:
A diversified, durable, high-value portfolio of medicines
- INDICATIONS UNDER STUDY
- CHRONIC GRAFT VERSUS HOST DISEASE (JP)
- CHRONIC NON-HEALING WOUNDS
- COMPLEMENT-MEDIATED DISEASES
- DIABETIC FOOT ULCERS
- HEPATIC ENCEPHALOPATHY
- HEPATIC ENCEPHALOPATHY (Oral)
- HEPATORENAL SYNDROME TYPE–1
- NIEMANN-PICK DISEASE TYPE C
- SEVERE BURNS, DEEP PARTIAL THICKNESS
- SEVERE BURNS, FULL THICKNESS
- SKIN CANCER RECURRENCE
- TBD
- All phases
- PRECLINICAL
- PHASE 1
- PHASE 2
- PHASE 3
- REGISTRATION
The safety and efficacy of these products for the indication under study have not yet been established by the relevant regulatory authorities.
UNDER STUDY
Learn More
Close
Graft versus Host Disease (GvHD) is a rare disorder that strikes bone marrow transplant or blood transfusion recipients whose immune system is deficient or suppressed. It can manifest as a skin rash, intestinal problems and liver dysfunction. It can be acute (sudden) or chronic (long lasting). Chronic GvHD lasts beyond 100 days and usually persists long after a bone marrow transplant.
How this therapy could help
Approximately 60% of bone marrow transplant patients develop GvHD, which is associated with high morbidity and mortality. Treatment with Extracorporeal Photopheresis for chronic GvHD is being studied in Japan.
Learn More
Close
Hepatorenal Syndrome Type 1 (HRS-1) is a life-threatening condition that consists of rapid deterioration in kidney function in individuals with cirrhosis or liver failure. HRS-1 affects from 10,000 to as many as 30,000 patients in the U.S. This condition can lead to multi-organ failure including acute kidney failure, and is often fatal unless a liver transplant is performed or the condition is reversed. There is no FDA-approved pharmacological therapy for treatment of HRS-1 in the U.S.
How this therapy could help
Reversal of HRS has been shown to increase survival and improve clinical outcomes. Terlipressin is the most widely studied and clinically accepted pharmacological therapy globally for patients with HRS-1.
Learn More
Close
Partial thickness burns (also known as second degree burns) affect the top two layers of skin. These burns can change over time and either heal or worsen into a full thickness (or third degree burn) after initial treatment. Partial thickness burns are serious and can become infected or be complicated by non-healing or abnormal scarring. The current standard of care for deep burns (partial or full thickness) includes skin-grafting (or autografting), which is the surgical harvest of healthy skin from an uninjured site on the patient’s body followed by transplant to the wound. It results in a donor site wound that requires medical management of pain, and may result in infection and/or scarring.
How this therapy could help
Results from a previous study in deep partial thickness burns demonstrated that StrataGraft skin tissue closed wounds and reduced the need for autografting. StrataGraft skin tissue is being studied as an alternative to autografting.
Learn More
Close
Niemann-Pick Type C (NPC) is a rare, neurodegenerative, and ultimately fatal disease that can present at any age. NPC is caused by mutations in either the NPC1 or NPC2 genes, resulting in the disruption of the trafficking of intracellular cholesterol, leading to intracellular lipid accumulation in various tissues, including the brain, liver, and spleen. Manifestations of the genetic disorder typically occur in childhood, with occasional late onset, and average diagnosis at ten years of age. NPC is usually fatal, and the majority of cases lead to death before age 20.
How this therapy could help
Results of a previous Adrabetadex study showed the potential for a disease-modifying effect based on slowing of progression on neurological, disease-specific outcomes measures and promising clinical improvements in patients with NPC. Adrabetadex is being studied further to assess safety and efficacy in patients with NPC.
Learn More
Close
Hepatic encephalopathy is a critical neurocognitive complication of chronic liver disease. It is associated with elevated circulating ammonia levels stemming from end stage liver disease (cirrhosis) and is generally reversible. Symptoms range from mildly altered mental status to coma or death. Once a patient suffers an acute hepatic encephalopathy episode, prevention of recurrence is critical and may require chronic therapy.
How this therapy could help
A goal of hepatic encephalopathy treatment is to lower blood ammonia levels. MNK-6105 has a novel mechanism of action that may help in eliminating excess ammonia in the bloodstream by excretion through the kidneys. An intravenous form of MNK-6105 is being studied in hospitalized patients with acute hepatic encephalopathy.
Learn More
Close
Full thickness burns (also known as third degree burns) affect all layers of the skin, and may cause damage down to underlying muscles. These burns carry severe risk for complications, such as infections, blood loss and shock, which could lead to organ failure or death. The current standard of care for severe burns is skin-grafting, or autografting, which is the surgical harvest of healthy skin from an uninjured site on the patient’s body followed by transplant to the wound. It results in a donor site wound that requires medical management of pain, and may result in infection and/or scarring.
How this therapy could help
A previous study in full thickness skin defects showed that StrataGraft skin tissue remained intact and viable throughout the seven-day placement period when it was used as a temporary cover to prepare the wound for skin-grafting. StrataGraft skin tissue is being studied further as a way to reduce the amount of autografting required in these patients.
Learn More
Close
Hepatic encephalopathy is a critical neurocognitive complication of chronic liver disease. It is associated with elevated circulating ammonia levels stemming from end stage liver disease (cirrhosis) and is generally reversible. Symptoms range from mildly altered mental status to coma or death. Once a patient suffers an acute hepatic encephalopathy episode, prevention of recurrence is critical and may require chronic therapy.
How this therapy could help
A goal of hepatic encephalopathy treatment is to lower blood ammonia levels. MNK-6105 has a novel mechanism of action that may help in eliminating excess ammonia in the bloodstream by excretion through the kidneys. An intravenous form of MNK-6105 is being studied in hospitalized patients with acute hepatic encephalopathy.
C9T1 skin tissue
Learn More
Close
Diabetic foot ulcers (DFU) are open sores or wounds that occur on the bottom of the foot in approximately 15% of patients with diabetes and are the cause of more hospitalizations than any other complication of diabetes. Of those who develop a foot ulcer, approximately 6% will be hospitalized due to infection or other ulcer-related complication.
How this therapy could help
ExpressGraft (C9T1 skin tissue) is the first genetically engineered human skin substitute in development that expresses therapeutic proteins and may help reduce infection and accelerate wound healing. ExpressGraft (C9T1 skin tissue) has been shown in preclinical studies to augment one of the skin’s native antimicrobial defense mechanisms. It is being further evaluated for its potential to promote the healing of chronic wounds, including diabetic foot ulcers.
Pro-Angiogenic (VEGF)
Learn More
Close
ExpressGraft (pro-angiogenic VEGF) is the first genetically engineered human skin substitute in development that expresses therapeutic proteins and may help reduce infection and accelerate wound healing. The pro-angiogenic properties of ExpressGraft provide sustained expression of human vascular endothelial growth factors (VEGF) that help to promote neovascularization and tissue regeneration within complex skin defects while providing a barrier function.
How this therapy could help
Potential applications include chronic wounds such as venous leg and/or diabetic foot ulcers, as well as acute wounds such as traumatic wounds that may require stimulation for neovascularization.
Anti-Tumor (IL-12)
Learn More
Close
ExpressGraft (IL-12) is the first genetically engineered human skin substitute in development that expresses therapeutic proteins and may help reduce infection and accelerate wound healing based on preclinical research. The anti-tumor properties of ExpressGraft (anti-tumor IL-12) provide sustained expression of human IL-12 and may suppress the growth of human skin cancer and secrete wound healing factors that may stimulate tissue regeneration.
How this therapy could help
A potential application may be following a surgical procedure for removal of a localized skin cancer.
(TOLL-LIKE RECEPTOR-9 (TLR-9) ANTAGONIST)
Learn More
Close
Acute pancreatitus is an inflammatory condition of the pancreas that is painful and at times fatal. The mortality rate of acute pancreatitis is about 10%. Sufferers often endure pain and malnutrition, and may be at higher risk of pancreatic cancer.
How this therapy could help
MP-3964, a TLR-9 antagonist, reduced serum markers of tissue injury, and reduced tissue inflammation and damage in both liver and pancreatic injury preclinical models. Further preclinical studies are ongoing to support a potential Investigational New Drug filing.
(RNAi)
Diseases
Learn More
Close
The complement cascade is a group of proteins that are involved in the immune system and that play a role in the development of inflammation. These proteins are known to contribute to the pathogenesis of many diseases, including autoimmune diseases.
How this therapy could help
The RNAi drug target is designed to inhibit the complement cascade.
DFU: Diabetic Foot Ulcer, DPT: Deep Partial Thickness, FT: Full Thickness, GvHD: Graft vs Host Disease, HRS: Hepatorenal Syndrome, JP: Japan, RNAi: Ribonecleic Acid interference, VEGF: Vascular Endothelial Growth Factor
*NPXe Limited is developing xenon gas for inhalation for the treatment of Post-Cardiac Arrest Syndrome. Mallinckrodt has licensed the rights to market xenon gas for inhalation in North America, Australia and Japan upon approval in each country.
**Collaboration with Silence Therapeutics